2000
THE EFFECT OF CYSTECTOMY, AND PERIOPERATIVE METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN CHEMOTHERAPY ON THE RISK AND PATTERN OF RELAPSE IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER
ENNIS R, PETRYLAK D, SINGH P, BAGIELLA E, O’TOOLE K, BENSON M, OLSSON C. THE EFFECT OF CYSTECTOMY, AND PERIOPERATIVE METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN CHEMOTHERAPY ON THE RISK AND PATTERN OF RELAPSE IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. Journal Of Urology 2000, 163: 1413-1418. DOI: 10.1097/00005392-200005000-00004.Peer-Reviewed Original ResearchRelapse-free survivalMuscle-invasive bladder cancerM-VAC chemotherapyLow-risk patientsInvasive bladder cancerRisk patientsPelvic failurePelvic relapseCisplatin chemotherapyBladder cancerMultivariate analysisIndependent poor prognostic factorCox proportional hazards modelMUSCLE INVASIVE BLADDERBenefit of chemotherapyHigh-risk featuresHigh-risk patientsPatterns of relapsePelvic lymph nodesKaplan-Meier methodPoor prognostic factorAmerican Joint CommitteePathological stage T3Proportional hazards modelExcellent disease controlTHE EFFECT OF CYSTECTOMY, AND PERIOPERATIVE METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN CHEMOTHERAPY ON THE RISK AND PATTERN OF RELAPSE IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER
ENNIS R, PETRYLAK D, SINGH P, BAGIELLA E, O’TOOLE K, BENSON M, OLSSON C. THE EFFECT OF CYSTECTOMY, AND PERIOPERATIVE METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN CHEMOTHERAPY ON THE RISK AND PATTERN OF RELAPSE IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. Journal Of Urology 2000, 163: 1413-1418. PMID: 10751847, DOI: 10.1016/s0022-5347(05)67632-x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinCombined Modality TherapyCystectomyDisease-Free SurvivalDoxorubicinFemaleHumansMaleMethotrexateMiddle AgedMuscle NeoplasmsMuscle, SmoothNeoplasm InvasivenessNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasm StagingRetrospective StudiesRisk FactorsTreatment FailureUrinary Bladder NeoplasmsVinblastineConceptsRelapse-free survivalMuscle-invasive bladder cancerM-VAC chemotherapyLow-risk patientsInvasive bladder cancerRisk patientsPelvic failurePelvic relapseCisplatin chemotherapyBladder cancerMultivariate analysisIndependent poor prognostic factorCox proportional hazards modelMUSCLE INVASIVE BLADDERBenefit of chemotherapyHigh-risk featuresHigh-risk patientsPatterns of relapsePelvic lymph nodesKaplan-Meier methodPoor prognostic factorAmerican Joint CommitteePathological stage T3Proportional hazards modelExcellent disease control
1999
Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients
Lee N, Newhouse J, Olsson C, Benson M, Petrylak D, Schiff P, Bagiella E, Malyszko B, Ennis R. Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology 1999, 54: 490-494. PMID: 10475360, DOI: 10.1016/s0090-4295(99)00150-8.Peer-Reviewed Original ResearchConceptsPositive CT scanGleason scoreComputed tomography scanCT scanClinical stageProstate cancerIndependent predictorsTomography scanSerum prostate-specific antigen levelProstate-specific antigen levelClinical stage T2bLow-risk patientsBiopsy Gleason scoreGleason score 8Negative CT scanAbdominopelvic CT scansGleason score 2Low-risk groupSignificant independent predictorsProstate cancer biopsiesStage T2bPathologic reviewStaging evaluationPositive CTAntigen levels